IN2014MN02274A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02274A
IN2014MN02274A IN2274MUN2014A IN2014MN02274A IN 2014MN02274 A IN2014MN02274 A IN 2014MN02274A IN 2274MUN2014 A IN2274MUN2014 A IN 2274MUN2014A IN 2014MN02274 A IN2014MN02274 A IN 2014MN02274A
Authority
IN
India
Prior art keywords
antibodies
fragments
therapy
stroke
treatment
Prior art date
Application number
Inventor
Moses Rodriguez
Arthur E Warrington
Larry R Pease
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of IN2014MN02274A publication Critical patent/IN2014MN02274A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Specific binding members particularly human antibodies particularly recombinant antibodies and fragments thereof which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful in the diagnosis and treatment of conditions associated with nerve damage injury or degeneration and neurodegenerative disease and in particular in the treatment or alleviation of stroke or cerebral ischemia. The antibodies variable regions or CDR domain sequences. thereof and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics immune modulators or neuroactive agents and/or with other antibodies or fragments thereof. The antibodies or active fragments thereof may be used in therapy for stroke or cerebral ischemia alone or in combination with thrombolytics such as TPA. Antibodies are exemplified by the antibodies lgM12 and lgM42 whose sequences are provided herein.
IN2274MUN2014 2012-04-17 2013-04-17 IN2014MN02274A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261625628P 2012-04-17 2012-04-17
PCT/US2013/036947 WO2013158748A1 (en) 2012-04-17 2013-04-17 Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions

Publications (1)

Publication Number Publication Date
IN2014MN02274A true IN2014MN02274A (en) 2015-08-07

Family

ID=49384031

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2274MUN2014 IN2014MN02274A (en) 2012-04-17 2013-04-17

Country Status (13)

Country Link
US (1) US20150104460A1 (en)
EP (2) EP2838562B1 (en)
JP (5) JP6162219B2 (en)
CN (2) CN104379167B (en)
BR (1) BR112014025898A2 (en)
CA (1) CA2870625C (en)
ES (2) ES2870717T3 (en)
HK (3) HK1206997A1 (en)
IL (2) IL235118B (en)
IN (1) IN2014MN02274A (en)
MX (1) MX356347B (en)
NZ (1) NZ701278A (en)
WO (1) WO2013158748A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060099203A1 (en) * 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
BR112016022841B1 (en) * 2014-04-03 2023-09-26 Igm Biosciences, Inc IGM, IGA, IGG/IGM OR IGG/IGA ANTIBODY COMPRISING A MODIFIED CHAIN
CA2967026A1 (en) * 2014-11-07 2016-05-12 Mayo Foundation For Medical Education And Research Treatment of neonatal hypoxia including impairments or effects thereof
KR20220018081A (en) 2015-03-04 2022-02-14 아이쥐엠 바이오사이언스 인코포레이티드 Cd20 binding molecules and uses thereof
JP7065766B2 (en) 2015-09-30 2022-05-12 アイジーエム バイオサイエンシズ インコーポレイテッド Bonded molecule with modified J chain
CN113035298B (en) * 2021-04-02 2023-06-20 南京信息工程大学 Drug clinical trial design method for recursively generating large-order line limiting coverage array
CN113444787A (en) * 2021-07-05 2021-09-28 中山大学附属第七医院(深圳) Lipid biomarker for autism and application thereof
CN114276418A (en) * 2021-12-28 2022-04-05 中国科学技术大学 RNA for target treatment of microtubule regulation and demyelinating lesions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CA2409515C (en) * 2000-05-10 2015-11-24 Mayo Foundation For Medical Education & Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
EP1648427B1 (en) 2003-05-16 2013-12-18 Mayo Foundation For Medical Education And Research Low dose IgM antibody treatment of demyelinating disorders
JP5452835B2 (en) * 2003-07-15 2014-03-26 中外製薬株式会社 Production of IgM by transformed cells and its quantification method
EP2481750A1 (en) * 2004-06-30 2012-08-01 Mayo Foundation for Medical Education and Research B7-DC binding antibody
WO2006029184A2 (en) * 2004-09-08 2006-03-16 Expression Diagnostics, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
WO2007109307A2 (en) * 2006-03-20 2007-09-27 Curagen Corporation Antibodies directed to angiopoietin-like protein 4 and uses thereof
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
WO2009052374A2 (en) * 2007-10-18 2009-04-23 Mayo Foundation For Medical Education And Research Igm-mediated receptor clustering and cell modulation
TW200950808A (en) * 2008-05-13 2009-12-16 Genentech Inc Anti-PirB antibodies
EP2621954A1 (en) * 2010-10-01 2013-08-07 Oxford Biotherapeutics Ltd. Anti-rori antibodies
CN103429260B (en) * 2010-10-19 2016-08-10 梅奥医学教育和研究基金会 For treating people's antibody of sacred disease and diagnosis thereof and therapeutic use
CA2967026A1 (en) * 2014-11-07 2016-05-12 Mayo Foundation For Medical Education And Research Treatment of neonatal hypoxia including impairments or effects thereof

Also Published As

Publication number Publication date
MX356347B (en) 2018-05-23
CN104379167B (en) 2018-02-13
EP3305323B1 (en) 2021-02-17
CN108285483A (en) 2018-07-17
JP2021000120A (en) 2021-01-07
IL266658B (en) 2021-04-29
CA2870625C (en) 2023-06-20
IL266658A (en) 2019-07-31
CN108285483B (en) 2022-04-26
BR112014025898A2 (en) 2017-11-07
EP2838562A1 (en) 2015-02-25
US20150104460A1 (en) 2015-04-16
EP3305323A1 (en) 2018-04-11
ES2655077T3 (en) 2018-02-16
JP2017127329A (en) 2017-07-27
HK1206997A1 (en) 2016-01-22
NZ701278A (en) 2016-12-23
ES2870717T3 (en) 2021-10-27
CA2870625A1 (en) 2013-10-24
IL235118B (en) 2019-06-30
WO2013158748A1 (en) 2013-10-24
JP2015520608A (en) 2015-07-23
HK1258380A1 (en) 2019-11-08
CN104379167A (en) 2015-02-25
IL235118A0 (en) 2014-12-31
HK1207565A1 (en) 2016-02-05
JP2022107016A (en) 2022-07-20
JP6162219B2 (en) 2017-07-12
EP2838562A4 (en) 2015-09-30
JP2019050832A (en) 2019-04-04
MX2014012651A (en) 2015-05-07
EP2838562B1 (en) 2017-08-30

Similar Documents

Publication Publication Date Title
IN2014MN02274A (en)
WO2012054077A3 (en) Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
CY1121097T1 (en) HUMAN ANTIBODIES AGAINST TOY GFR 3 AND METHODS OF USING THEM
MX2022004300A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration.
PH12016501456A1 (en) Antibody molecules to pd-1 and uses thereof
MY169328A (en) Compositions for the treatment of dry eye
HK1210968A1 (en) Compositions and treatment for eye diseases and disorders
MX356800B (en) Humanized tau antibody.
WO2013061161A3 (en) New combination therapies for treating neurological disorders
IL237743A0 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular hutington's disease
BR112018009891A2 (en) extracellular neural cell vesicles
IN2014DN06792A (en)
MX2016010953A (en) Multimeric fc proteins.
EA201500363A8 (en) HUMAN ANTI-VEGFR-2 / KDR-ANTIBODIES
DK2714888T3 (en) RECOMBINANT DO
EA201492102A1 (en) ANTAGONISTS LINGO-2 FOR THE TREATMENT OF DISEASES IN WHICH MOTOR NEURONS PARTICIPATE
MX2015008117A (en) Anti-h7cr antibodies.
EA201500370A1 (en) PHARMACEUTICAL COMBINATIONS CONTAINING DOUBLE ANGIOPOETIN-2 / Dll4 BINDING AGENTS AND ANTI-VEGF-R AGENTS
WO2015080980A3 (en) Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
MX366046B (en) Binding molecules that bind human complement factor c2 and uses thereof.
MX345534B (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases.
WO2014083432A3 (en) Female intranasal testosterone gel for treating anorgasmia
MX2013006633A (en) Beta-hydroxy-gamma-aminophosphonates for treating immune disorders.
TH1601002196A (en) Use of semaphorin-4D binding molecule For the treatment of disease disorders Destruction of nerve cells in the brain (neurodegenerative disorder)
BR112015032554A2 (en) BRADYKININ RECEPTOR MODULATORS AND THEIR USE